March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Explore our third tip in our series aimed at refining asynchronous virtual meetings. Discover how using blinded questions can significantly minimize bias and enhance the integrity of feedback in virtual…
Uncover the second crucial tip for optimizing your asynchronous virtual meetings. Learn the importance of scale consistency in survey-style questions on the Impetus InSite Platform to ensure clear and reliable…
To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical…
Unlock the potential of asynchronous virtual meetings with the first tip from our “Top 10 Tips for Optimizing Asynchronous Virtual Meetings”.
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.
This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences…
Register now for one of our upcoming webinars (February 26-28)
In this quick clip, we highlight a vital tip from our ‘Top 10 Most Important Advisor Questions’ – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences….
Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient…
In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today’s diverse healthcare landscape. 7….
